Hancock Story

Do analysts believe Hancock Jaffe (NASDAQ:HJLI) will continue to rise?
What is the right price you would pay to acquire a share of Hancock Jaffe? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

How important is Hancock Jaffe's Liquidity

Hancock Jaffe financial leverage refers to using borrowed capital as a funding source to finance Hancock Jaffe Laboratories ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Hancock Jaffe financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Hancock Jaffe's total debt and its cash.

How Hancock utilizes its cash?

To perform a cash flow analysis of Hancock Jaffe, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Hancock Jaffe is receiving and how much cash it distributes out in a given period. The Hancock Jaffe cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Hancock Jaffe Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (5.31 Million)

Acquisition by Jenusaitis Matthew of 100000 shares of Hancock Jaffe subject to Rule 16b-3

Legal trades by Hancock Jaffe insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Hancock insider trading alert for grant of stock option (right to buy) by Jenusaitis Matthew, the corporate stakeholder, on 21st of October 2020. This event was filed by Hancock Jaffe Laboratorie with SEC on 2020-10-21. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

About Contributor